Abstract: A composition of matter which consists of (a) from about 16.7 to about 22.2% by weight of at least one compound selected from the group consisting of linolenic acid and derivatives thereof, calculated as the free acid, said derivatives of linolenic acid being both physiologically hydrolyzable and pharmacologically acceptable, and (b) about 77.8 to about 83.3% by weight of at least one compound selected from the group consisting of linoleic acid and derivatives thereof, calculated as the free acid, said derivatives of linoleic acid being both physiologically hydrolyzable and pharmacologically acceptable, is utilized e.g. as a pharmaceutical formulation or nutritional composition, in absence of an oily carrier or diluent which comprises at least one member of the group consisting of C.sub.
Abstract: A composition of matter which consists of (a) from about 13.0 to about 27.5% by weight of at least one compound selected from the group consisting of linolenic acid and derivatives thereof, calculated as the free acid, said derivatives or linolenic acid being both physiologically hydrolyzable and pharmacologically acceptable, and (b) about 87.0 to about 72.5% by weight of at least one compound selected from the group consisting of linoleic acid and derivatives thereof, calculated as the free acid, said derivatives of linoleic acid being both physiologically hydrolyzable and pharmacologically acceptable, is utilized e.g. as a pharmaceutical formulation or nutritional composition, in absence of an oily carrier or diluent which comprises at least one member of the group consisting of C.sub.
Abstract: The invention provides a novel antibacterial compound and a process for producing it. Futhermore, the invention provides a novel antibacterial polymer composite comprising a polymer and the antimicrobial compositon.
Type:
Grant
Filed:
May 17, 1993
Date of Patent:
May 9, 1995
Assignees:
Hagiwara Research Corp., Japan Electronic Materials Corp.
Abstract: Ferritin analogs comprising an apoferritin protein shell and a core substantially devoid of ferrihydrite, e.g. of inorganic composition such as aluminum hydroxide or organic composition such as acetaminophen. The protein shell can be removed from ferritin analog to produce spherules having a substantially monomodal nominal diameter between about 45 and 90 Angstroms.
Abstract: A nutritional supplement, functioning as a food for special dietary use, enhances diets and assists persons recovering from addiction to health damaging substances. Since cellular damage and deficiencies occur and continue to exist even after the person has stopped abusing the substances, use of the nutritional supplement, which contains a variety of minerals, vitamins, herbs, amino acids, and other substances and nutrients, should be continuous. The nutritional supplement consists of a mixture of nutrients which cooperate synergistically in enhancing cellular metabolic pathways and assists in normalization of cellular functions and optimization of cellular health.
Abstract: A nutritional supplement, functioning as a food for special dietary use, enhances diets and assists persons recovering from addiction to health damaging substance(s). Since cellular damage and deficiencies occur and continue to exist even after the person has stopped abusing the substance(s), use of the nutritional supplement, which contains at least one enzyme activating substance and at least one enzyme cofactor, should be continuous. The nutritional supplement consists of a mixture of nutrients which cooperate synergistically in enhancing cellular metabolic pathways and assists in normalization of cellular functions and optimization of cellular health.
Abstract: The present invention provides a novel antimicrobial composition and a process for preparing the composition which composition is useful as antimicrobial and/or bactericidal material. The antimicrobial composition of the invention comprises silica gel and an antimicrobial coat of aluminosilicate on the surface of the silica gel, said composition having a pore volume of at least 0.3 cm.sup.3 /g and a specific surface area of at least 100 m.sup.2 /g. The aluminosilicate coat consists of either partial or complete substitution of ion-exchangeable metal ion (M) in aluminosilicate solid particles represented by the formulaxM.sub.2/n O.Al.sub.2 O.sub.3.ySiO.sub.2.zH.sub.2 O,wherein x and y represent the numbers of molecules of the metal oxide and silicon dioxide, respectively, M is an ion-exchangeable metal, n is the atomic valence of M, and z is the number of molecules of water.
Type:
Grant
Filed:
February 28, 1991
Date of Patent:
September 14, 1993
Assignees:
Hagiwara Research Corp., Japan Electronic Materials Corporation
Abstract: The present invention relates to oral effervescent dosage forms for the administrations of an intended ingredient to children, and processes for their administration.
Type:
Grant
Filed:
August 26, 1991
Date of Patent:
June 29, 1993
Assignee:
Cima Labs, Inc.
Inventors:
Fred Wehling, Steve Schuehle, Navayanarao Madamala
Abstract: A process for obtaining a material possessing glucose tolerance factor activity and capable of binding with insulin including the steps of (i) contacting a eukaryotic cell mass with a mixture of water and alcohol to form a water phase and an alcohol phase; (ii) separating the alcohol phase from the water phase and isolating a water phase extract; and (iii) subjecting the water phase extract to gel exclusion chromatography, eluting all material having a molecular weight of approximately 720 to 1120 to obtain a material possessing glucose tolerance factor activity and capable of binding with insulin.
Abstract: A substance with therapeutic applications comprises, in aqueous solution:(1) at least one organo-silicon compound having either of the following formulas: ##STR1## in which: n is an integer between 1 and 1000, and preferably between 1 and 50;p, q, r are integers between 0 and 1000, and preferably between 0 and 60;R and R' represent, independently of one another, a linear aliphatic group, branched or cyclic, saturated or not, hetero-linear branched or not, cyclic saturated or not, aromatic, heteroaromatic, arylaliphatic, or heteroarylaliphatic, which may also be functional, whilst R may also be OH, OR or OSiR.sub.3 ;.SIGMA. is R, H or SiR.sub.3, where R is as previously defined;.SIGMA.' is R and more particularly CH.sub.3, OR, OH or OSiR.sub.
Type:
Grant
Filed:
March 22, 1990
Date of Patent:
February 19, 1991
Assignees:
Loic Le Ribault, Rene Nardou, Michel Bonnaval-Lamothe
Abstract: Prevention of or therapeutically curing the disease of alcoholism comprises supplementing the diet with biologically available chromium, such as naturally occurring chelated chromium.
Abstract: The radionuclide Tin, Sn-121 in a carrier hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis of the hands, the interphalangeal joints of the fingers and the metacarpal joints of the hand.The radioactive compound disclosed preferably has a particle size of <90 microns. The beta energy emission associated with Tin, Sn-121 has an energy of 0.38 meV. There are no gamma photons emited during the decay of Tin, Sn-121 to stable Antimony Sb-121. The half life of Tin, Sn-121 is 27.06 hours.The method of preparation of the compound is disclosed along with the method of administration to the patient in need thereof.
Type:
Grant
Filed:
March 26, 1987
Date of Patent:
March 6, 1990
Inventors:
Ephraim Lieberman, Maurice E. Bordoni, Alfred K. Thornton